Lenhart – Oral Sedation for Children and Adults Part 3-Lenhart – Oral Sedation for Children and Adults Part 3

Video Transcription

Video Summary

The lecture introduces core pharmacology principles for safe pediatric dental sedation, emphasizing that dosing is not a “cookbook” but a risk-managed approach within the AAPD’s conservative safety margins. The speaker contrasts dentistry’s smaller doses with medicine’s larger doses (enabled by heavier monitoring), warning that combining drugs (plus nitrous oxide and local anesthetic) produces synergistic—not merely additive—sedation, so doses must be reduced.<br /><br />Key pharmacokinetic concepts include absorption, distribution, metabolism (notably liver/CYP450), and excretion. Oral and rectal routes are highlighted as erratic, affected by stomach contents, formulation, age, disease states, protein binding (albumin), body fat “depot” storage, circadian rhythms (deeper sedation later in the day), and drug interactions. Inhaled agents like nitrous are eliminated via lungs and other routes. The lecture also reviews first-order kinetics, half-life, bioavailability, therapeutic index (wide for benzodiazepines, narrow for chloral hydrate), potency vs efficacy, tolerance, and receptor concepts (agonists/antagonists, affinity/selectivity).<br /><br />Route limitations depend on sedation permits; sublingual/intranasal can bypass first-pass metabolism and deepen sedation unexpectedly.<br /><br />Drug overview: chloral hydrate is effective but outdated due to unpredictable onset, long duration (4–8 hours), GI upset, no reversal agent, and low safety margin. Antihistamines (diphenhydramine, hydroxyzine) are very safe adjuncts with antiemetic and drying effects but can cause paradoxical excitation, especially in children. Benzodiazepines (diazepam, midazolam, triazolam, lorazepam) provide anxiolysis, sedation, and amnesia; midazolam is short-acting and reversible with flumazenil, though resedation is a risk due to flumazenil’s short half-life. Opioids add analgesia and sedation but increase nausea, histamine release, and respiratory depression; naloxone reverses them abruptly and can trigger agitation/vomiting. Nitrous oxide is a titratable adjunct but higher concentrations raise vomiting risk.

Keywords

pediatric dental sedation

AAPD safety margins

risk-managed dosing

synergistic drug interactions

pharmacokinetics absorption distribution metabolism excretion

CYP450 hepatic metabolism

oral and rectal route variability

first-pass metabolism bypass (intranasal/sublingual)

half-life and first-order kinetics

bioavailability and therapeutic index

benzodiazepines (midazolam) and flumazenil reversal

chloral hydrate safety concerns

opioids respiratory depression and naloxone reversal